logo
  

Merck KgaA Signs Deal With IB To Support Establishment Of Vaccine Production Facility In Nigeria

German drug giant Merck KgaA (MKGAY.PK) said that it has signed an agreement with biotechnology company Innovative Biotech to design the manufacturing process for the first vaccine production facility in Nigeria.

The collaboration is part of the West African pandemic readiness program, which aims to localize vaccine development in the African nations. The first phase of the partnership focuses on designing the fill and finish facility, incorporating the company's Mobius single-use technology, while the second phase will focus on enabling continuous manufacturing.

Innovative Biotech's licensor, TechnoVax, is developing a virus-like-particle (VLP)-based vaccine to target variants of Covid-19.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Apple Inc. may face production shortfall of as many as 6 million iPhone Pro units this year due to ongoing protests at its major China plant, Bloomberg reported citing a person familiar with assembly operations. Following the news, Apple shares were losing around 2.2 percent in pre-market activity on the Nasdaq. Despite fears of inflation, consumers spent $9.12 billion for online shopping during Black Friday, higher than in previous years, as per a report published by Adobe Analytics. During the 2022 holiday season, total estimated revenues are $209.7 billion, a growth of 2.5 percent from last year's recorded revenues of $205 billion. Weis Markets, Inc., a Mid Atlantic food retailer, has recalled 108 containers of Weis Quality Sea Salt Caramel Ripple Ice Cream citing possible presence of undeclared soy and coconut allergens, the U.S. Food and Drug Administration said. The recalled product comes in 48oz containers that says Weis Quality Sea Salt Caramel Ripple Ice Cream, while the lid says Weis Quality Caramel Caribou Ice Cream
Follow RTT